EUCTR2014-004860-39-IT进行中（未招募）1 期
A phase I/II study evaluating safety and efficacy of autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin gene for the treatment of patients affected by transfusion dependent beta-thalassemia - TIGET-BTHA
OSPEDALE SAN RAFFAELE0 个研究点目标入组 10 人开始时间: 2014年11月21日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Written informed consent
- •Transfusion-dependent beta-thalassemia (any genotype). Transfusion dependence is defined as receiving = 8 transfusions of blood per year over a minimum of 2 years.
- •Karnofsky Index or Lansky > 80%
- •Age = 3 years and < 65 years
- •Adequate cardiac, renal, hepatic and pulmonary functions as evidenced by:
- •?Left ventricular ejection fraction (LVEF) greater than 45% by echo and normal ECG or presence of abnormalities not significant for cardiac disease. Absence of severe pulmonary hypertension
- •?Diffusing capacity of the lung for carbon monoxide (DLCO) > 50% and forced expiratory volume in 1 sec (FEV1) and forced expiratory vital capacity (FVC) > 60% predicted
- •(if non cooperative: pulse oximetry > 95 % in room air)
- •?Serum creatinine < 1.5 upper limit of normal
- •?Absent-mild-moderate liver iron overload on T2*MRI (less than 12 months before enrolment)
- •?Absent-mild-moderate cardiac iron overload T2*MRI (less than 12 months before enrolment)
- •?Absence of severe liver fibrosis or cirrhosis on fibroscan or liver biopsy (less than 12 months before enrolment)
- •Low risk thrombophilic screen and negative history of significant previous thrombotic events
- •For all patients in reproductive age, agreement to use highly effective and adequate method of contraception while receiving treatment phase and for at least 12 months following drugs administration (including both females of child bearing potential and males with partners of child bearing potential)
- •Good adherence to transfusion and chelation programme as indirect evidence of good adherence to treatment and follow-up evaluations for current trial
- •Availability of an adequate and well documented transfusion history (at least previous 6 months) or availability to follow a regular transfusion regimen according to guidelines and provide a detailed transfusion record of the 6 months prior to intervention phase
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 7
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 3
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Use of other investigational agents within 4 weeks prior to study enrolment (within 6 weeks if use of long-acting agents)
- •Severe, active viral, bacterial, or fungal infection at eligibility evaluation
- •Malignant neoplasia (except local skin cancer or cervical intraepithelial neoplasia) or exceptional family history of familial cancer syndromes
- •Myelodysplasia, cytogenetic alterations associated with neoplasia, or other serious haematological disorder than thalassemia
- •History of uncontrolled seizures
- •Other clinical conditions judged non compatible with the procedure and/or the treatment
- •Positivity for HIV (serology or RNA), and/or HbsAg and/or HBV DNA and/or HCV RNA (or negative HCV RNA but on antiviral treatment) and/or Treponema Pallidum or Mycoplasma active infection
- •Active alcohol or substance abuse within 6 months of the study
- •Pregnancy or lactation
- •Previous allogeneic bone marrow transplantation or gene therapy
- •For paediatric patients only: availability of an HLA-matched donor (sibling or of a suitable 10/10 matched unrelated donor).
研究者
相似试验
进行中（未招募）
1 期
Gene therapy study with autologous hemapoietic stem cells for patients affected by MPSIHEUCTR2017-002430-23-ITOSPEDALE SAN RAFFAELE6
进行中（未招募）
1 期
Gene therapy study with autologous hemapoietic stem cells for patients affected by MPSIHMucopolysaccharidosis type I HurlerCTIS2024-514870-29-00Ospedale San Raffaele S.r.l.8
进行中（未招募）
1 期
Evaluation of safety and efficacy of DCVAC/LuCa (immunotherapy of lung cancer) in patients with metastatic lung cancerStage IV Non-Small Cell Lung CancerMedDRA version: 20.1Level: PTClassification code 10025070Term: Lung carcinoma cell type unspecified stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003084-37-CZSOTIO a.s.98
进行中（未招募）
1 期
Evaluation of safety and efficacy of DCVAC/LuCa (immunotherapy of lung cancer) in patients with metastatic lung cancerStage IV Non-Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10025070Term: Lung carcinoma cell type unspecified stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003084-37-SKSOTIO a.s.98
已完成
1 期
A clinical trial to study safety and effects of P276-00 in combination with Gemcitabine in treatment of pancreatic cancer .CTRI/2009/091/000214Piramal Life Sciences Limited23